ASX 200 healthcare shares were chronically ill last quarter. Take a look

They aren't exactly on the mend either.

| More on:
a woman rugged up in a woolen hat and gloves with a thermometer in her mouth props her hand under her chin as she looks dejectedly at the camera,, as though she is miserable from feeling sick.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX 200 healthcare shares are taking a beating so far in 2022
  • Losses have spilled over from the previous year with many names deep in the red last quarter
  • Earnings for the sector are also estimated to fall, analysis shows

ASX 200 healthcare shares have struggled for the past six months, let's face it. After peaking at 52-week highs of 47,760 back in September 2021, the S&P/ASX 200 Health Care Index (ASX: XHJ) now rests at 39,861. That's a 16.5% decline over that time.

In the meantime, other sectors – mining and financials in particular – have thrust well above the laggards in sectors like healthcare and tech.

The divergence continues to widen as well. Since the onset of geopolitical conflict, commodity inflation, and a shifting interest rate cycle, ASX 200 healthcare shares are bottom-heavy and now trade near 52-week lows.

TradingView Chart

Pseudo-top performers

Categorising the 'top' performers amongst this group is a bit of a fallacy. According to Bloomberg data, only one name – Cochlear Ltd (ASX: COH) – finished higher for the period, with a 5% gain.

Otherwise, the basket faced heavy losses for the quarter. Indeed, ranking in terms of performance is more an exercise in 'who fell more than the other'.

In terms of percentage change, Telix Pharmaceuticals Ltd (ASX: TLX) took out top spot with a heavy 40.2% loss for the period. Telix now needs to gain 66.7% to return to its pre-January levels.

But losses were heavy for the sector overall. The average loss for an ASX healthcare stock was 20.82% last quarter, calculated from Bloomberg data.

Names such as Imugene Ltd (ASX: IMU), Nanosonics Ltd (ASX: NAN), Clinuvel Pharmaceuticals Ltd (ASX: CUV), and Fisher & Paykel Healthcare Corp. Ltd (ASX: FPH) each fell further than the average.

Meanwhile, CSL Ltd (ASX: CSL), Ramsay Health Care Ltd (ASX: RHC), and ResMed Inc (ASX: RMD) managed to close out the quarter in much less pain.

Returns for the group and respective tickers for the top 10 performers last quarter are plotted below, in descending order.

TradingView Chart

Not only that, but earnings per share (EPS) for the sector is estimated to slide further in 2022, after already taking a backward step since September 2021.

According to Bloomberg consensus data, by this time next year, analysts are forecasting the healthcare sector's EPS to slide another 17% on average.

Curiously, the data also shows the consensus of analyst estimates predicts a negative 17 cents EPS for Telix in the next period and Imugene a negative 1 cent per share EPS loss. That's in line with the EPS loss of 20 cents in 2020 for Telix but behind 2019's result.

Meanwhile, CSL and Cochlear are estimated to deliver a $6.87 and $4.28 EPS result in the next period, according to Bloomberg consensus data.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 3 April 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd., Cochlear Ltd., and Nanosonics Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia owns and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd., Ramsay Health Care Limited, and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Share Gainers

Guess which ASX All Ords stock just rocketed 28% on a new commercial contract!

The ASX All Ords stock has grabbed plenty of investor interest on Tuesday.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Is the CSL share price a buy? Here's a top broker's view

Is this stock a healthy opportunity? Let’s have a look.

Read more »

Man ecstatic after reading good news.
Healthcare Shares

Which ASX company has just secured FDA approval?

This stock just announced some big news.

Read more »

Health professional putting on gloves.
Healthcare Shares

How will Ansell shares navigate tariffs according to Macquarie?

The next two years could be a challenging period for the PPE company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is surging 18% on big news

This stock is getting a lot of love from investors on Monday.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Healthcare Shares

CSL shares are having a tough time recently. Are they a buy or a sell?

Is now a good time to jump in and buy this blue chip star?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

This high-flying stock has suffered from turbulence.

Read more »